|  |  |
| --- | --- |
| A picture containing text, clipart  Description automatically generated | Logo  Description automatically generated |
| **(PETROLEUM, COAL & RELATED PRODUCTS DEPTT.)** |
| **RESOLUTIONS** |
| **39th Meeting of Cosmetics Sectional Committee, PCD 19**  |
| **DAY, DATE & TIME** | **Friday, 30-08-2024 & 11:30 a.m.** |
| **MEETING MODE** | **VIRTUAL MEETING** |
| **CHAIRPERSON** | **Dr. Rajeev Singh Raghuvanshi, Drugs Controller General (India)**  |
| **MEMBER SECRETARY** | Shri Rajat Gupta, Scientist ‘C’/ Deputy Director (PCD), BISE-mail: pcd19@bis.gov.in  |

***Resolution PCD19/2024:01/R-1***

The Committee decided to change the nomenclature of existing sub-committees to panels and existing panels to working groups.

**2.3 Requests for representation in Cosmetics Sectional Committee, PCD 19**

The Committee decided to Co-opt PETA India since it is an NGO. The Committee decided that the industries whose co-option request has been received shall participate on behalf of Industry Associations. The Committee further decided to review the co-option requests received from Industry Associations in the next meeting along with the review of the industries already existing in the committee.

***Resolution PCD19/2024:01/R-2***

1. Dr. Benedict informed the committee that the working draft on ‘Labelling and Claims for the natural and organic cosmetics’ will be submitted by October 2024 end and will be circulated to the committee for comments.
2. Dr. Benedict informed the committee that the draft revision of IS 4011 : 2018 Methods of Test for Safety Evaluation of Cosmetics (Third Revision) will be submitted by October 2024 end. The Committee further decided to organize a webinar/workshop on ‘NGRA (Next generation Risk Assessment) methods’ latest by October 2024.
3. IBHA informed the committee that the inputs on the Horizontal/ Safety Standards available world over and a New Work Item Proposal (NWIP) for deliberation in the Committee will be provided by them within a month.

***Resolution PCD19/2024:01/R-3***

1. The Committee decided to deliberate the comments received on Doc. No. PCD 19/15096, PCD 19/19476, PCD 19/19479, PCD 19/19493 and PCD 19/24649 in the respective panels and will be taken up in the next meeting.
2. The Committee finalized the Doc. No. PCD 19/17644, PCD 19/17647, PCD 19/19444, PCD 19/23405 and PCD 19/23425 and decided to send it for printing.
3. The Committee decided to reissue the draft received from Godrej CP on IS 14648 : 2011 in wide circulation for 2 months with a new document number.
4. The Committee decided to hold the printing of Doc. No. PCD 19/19461 since IS 18822 : 2024/ISO 16408:2015 is already available. The Committee further decided to compare the Doc. No. PCD 19/19461 with IS 18822 : 2024/ISO 16408:2015 and inform the changes, if any, in the next meeting.
5. The Committee decided to finalize the Doc. No. PCD 19/19573 by incorporating the sub-committee recommendations and comments received from Mr. Ashish Yekhe and decided to send it for printing.
6. The Committee deliberated on the comments received by IBHA on Doc. No. PCD 19/20109 and agreed with the comments. The Committee further decided to finalize the Doc. No. PCD 19/20109 by incorporating the sub-committee recommendations and agreed changes and decided to send it for printing.
7. The Committee deliberated on the comments received by Ms. Vrinda on Doc. No. PCD 19/20742 and agreed with the comments. The Committee further decided to finalize the Doc. No. PCD 19/20742 by incorporating the sub-committee recommendations and agreed changes and decided to send it for printing.

***Resolution PCD19/2024:01/R-4***

1. The Committee deliberated on the comments received by Juris&Juris on IS 4707 (Part 2) : 2017 and disagreed with their comments. The Committee thoroughly reviewed the issue and decided to endorse the panel's recommendations, while rejecting the comments submitted by Juris&Juris. The Committee rejected comments of Juris&Juris because of the absence of required safety reports and the fact that the molecule ‘Chlorhexidine di-undecylenate’ (commonly known as Salibact) is not referenced in any existing regulations globally.
2. The Committee decided to deliberate the comments received on IS 10377 : 2024 from Loreal India Ltd. in the respective panel.
3. The Committee decided to deliberate the amendment proposals received on IS 6356 : 2021 by Colgate-Palmolive (India) Ltd. and IS 3959 : 2023 by HUL, in the respective panels.

***Resolution PCD19/2024:01/R-5***

**6.1 Review/reaffirmation of Indian standards**

a) The Committee decided to reaffirm the following the Standards:

IS 10350 : 2020, IS 1463 : 2020, IS 15467 : 2004, IS 4707 (Part 1) : 2020, IS 6608 : 2004, IS 8481 : 2020, IS 8482 : 2020, IS 9255 : 2020, IS 9339 : 2020, IS 17318 : 2020

b) The Committee decided to reaffirm and revise IS 10998 : 1984.

c) The Committee decided to reaffirm and archive the following Standards:

 IS 14318 : 1996, IS 14649 : 1999, IS 3986 : 1988, IS 4236 : 1999, IS 7101 : 1994.

**6.2** **Revision of Pre-2000 Indian standards**

The Committee decided to reaffirm and archive the following Standards:

 IS 2520 : 1984, IS 2521 : 1984, IS 2528 : 1984, IS 2529 : 1983, IS 2850 : 1983, IS 5340 : 1981, IS 5356 : 1977, IS 9245 : 1994, IS 9636 : 1988, IS 9830 : 1988, IS 11015 : 1984, IS 11023 : 1984, IS 12590 : 1988, IS 13965 : 1994, IS 918 : 1985, IS 1767 : 1980, IS 4028 : 1992, IS 7679 : 1978, IS 9601 : 1980, IS 9681 : 1980, IS 10283 : 1982, IS 11487 : 1985, IS 2519 : 1983, IS 263 : 1990, IS 2851 : 1983